Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04828265 · ClinicalTrials.gov registry record · Phase 1
Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects
A Phase 1 study of Healthy Male, sponsored by NGM Biopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT04828265 is a Phase 1 study of Healthy Male that has completed, run by NGM Biopharmaceuticals. The registered enrollment target is 36 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04828265, a Phase 1 study of Healthy Male, has completed, sponsored by NGM Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label study to assess safety, tolerability, and pharmacokinetics of Aldafermin (NGM282) in healthy adult male Japanese and non-Japanese subjects
Conditions Studied
Interventions
- BIOLOGICAL Aldafermin
Study Locations (1)
California
- NGM Clinical Study Site 112 - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-04-13 |
| Est. Completion | 2021-07-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04828265
The ClinicalTrials.gov registry entry for NCT04828265 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NGM Biopharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Male appearing as the primary indexed condition, and to 1 intervention - of which Aldafermin is the first listed.
NCT04828265 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04828265 about?
NCT04828265 is a clinical study titled "Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects". This is an open-label study to assess safety, tolerability, and pharmacokinetics of Aldafermin (NGM282) in healthy adult male Japanese and non-Japanese subjects
What is the current status of trial NCT04828265?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2021-04-13. Estimated completion is 2021-07-06.
What conditions does trial NCT04828265 study?
This clinical trial studies the following conditions: Healthy Male.
What interventions are being tested in trial NCT04828265?
The interventions under investigation include: Aldafermin (BIOLOGICAL).
Who is sponsoring clinical trial NCT04828265?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04828265 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.